Weight Loss Peptides

Retatrutide is sold here only as a research vial labeled for research use, shipped to addresses across the United States; the Retatrutide product page lists strengths and stock. It is not an approved medicine: FDA says retatrutide is not a component of any FDA-approved drug, cannot be used in compounding under federal law, and has not been found safe and effective for any condition.¹ FDA has also warned companies that sold research-labeled retatrutide directly to consumers for human use.¹

Federal rules let an unapproved new drug be shipped for test-tube or lab animal research only under a label ending "Not for use in humans," and only to buyers who regularly do such research.² FDA has called research-labeled tirzepatide an unapproved new drug when a seller's website showed it was meant for people, including in a March 2026 warning letter to an online seller.³ The Tirzepatide vial here is sold for laboratory research only, under our research use policy.

It is filed here, but MOTS-c is not an FDA-approved drug for any use.⁵ FDA's advisory committee reviewed it for obesity and osteoporosis in July 2026.⁴ Trade press reported a 7 to 5 vote, with 2 abstentions, recommending it for the pharmacy compounding list against the advice of FDA's career scientists, and noted that FDA must still act and go through rulemaking.⁵ The MOTS-c education page describes the published studies, which are the place to judge any effect on weight.